US20030050303A1 - Solutions containing epinastin - Google Patents
Solutions containing epinastin Download PDFInfo
- Publication number
- US20030050303A1 US20030050303A1 US10/271,180 US27118002A US2003050303A1 US 20030050303 A1 US20030050303 A1 US 20030050303A1 US 27118002 A US27118002 A US 27118002A US 2003050303 A1 US2003050303 A1 US 2003050303A1
- Authority
- US
- United States
- Prior art keywords
- aqueous solution
- epinastine
- solution
- concentration
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
- F01L—CYCLICALLY OPERATING VALVES FOR MACHINES OR ENGINES
- F01L9/00—Valve-gear or valve arrangements actuated non-mechanically
- F01L9/20—Valve-gear or valve arrangements actuated non-mechanically by electric means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T137/00—Fluid handling
- Y10T137/0318—Processes
Definitions
- the invention relates to topically administered aqueous solutions containing epinastin, optionally in the form of its racemates, its enantiomers and optionally in the form of the pharmacologically acceptable acid addition salts thereof.
- Allergic reactions of the eye signifies a series of differently defined syndromes.
- Examples of allergic reactions of the nose include seasonal allergic rhinitis and perennial allergic rhinitis, for example.
- the immunological mechanism on which ocular and nasal allergic reactions are based comprises, inter alia, inflammatory processes caused by histamine.
- the allergic reactions produced by the release of histamine occur at an early stage of the ocular and nasal allergic reactions mentioned above.
- ocular and nasal allergic reactions may be due to the release of other mast cell mediators as well as toxic eosinophilic granule proteins and enzymes.
- the influx of neutrophils and eosinophils into the tissue of the ocular conjunctiva and the nasal mucous membrane leads to a late phase reaction, hereinafter referred to as LPR.
- LPR normally occurs within a period of 3-6 hours after the initial histamine-mediated allergic reaction.
- LPR is also characterized by the occurrence of vasodilation and chemosis and by the swelling of the conjunctiva and the nasal mucous membrane.
- the problem of the present invention is therefore to provide topically administrable solutions which inhibit the influx of neutrophils and eosinophils into the tissue of the ocular conjunctiva and the nasal mucous membrane, thereby reducing or preventing the occurrence of LPR and are therefore characterized by a longer lasting duration of activity.
- topically administrable aqueous solutions containing epinastin, optionally in the form of its racemate, its enantiomers and possibly in the form of the pharmacologically acceptable acid addition salts thereof may be used to solve the problem on which the invention is based, since they inhibit the influx of neutrophils and eosinophils into the tissue of the ocular conjunctiva and nasal mucous membrane, thereby reducing or preventing the occurrence of LPR and are accordingly characterized by a longer lasting duration of activity.
- the animals pretreated with epinastin solution according to the invention (0.05-0.5%) had a significantly lower content of eosinophils in their conjunctiva.
- the animals pretreated with epinastin solution according to the invention had a significantly lower content of lymphocytes in their conjunctiva (p ⁇ 0.01).
- a roughly 35% inhibition of mast cell degranulation was determined (p ⁇ 0.01).
- the invention relates to topically administered aqueous solutions containing epinastin, optionally in the form of its racemate, its enantiomers and optionally in the form of the pharmacologically acceptable addition salts thereof, in a concentration of 0.005 to 0.5, preferably 0.02 to 0.1, most preferably 0.03 to 0.07 mg/ml of solution.
- Suitable aqueous solvents are physiologically acceptable aqueous solvents, physiologically acceptable saline solutions being particularly preferred.
- topically administered solutions are preferably prepared which typically contain 0.005 to 0.5, preferably 0.02 to 0.1, most preferably 0.03 to 0.07 mg/ml of epinastin, optionally in the form of its racemate, its enantiomers and optionally in the form of the pharmacologically acceptable acid addition salts thereof, as well as physiological saline solutions as the main carriers.
- the pH of the solutions according to the invention should preferably be maintained within the range from 6.5 to 7.2 by means of a suitable buffer system.
- the preparations may also contain conventional, pharmaceutically acceptable excipients, preservatives, stabilizers and/or penetration promoters.
- the preferred carrier which may be used in the solutions according to the invention is purified water and preferably a physiological saline solution.
- the excipients which may be used according to the invention include viscosity agents such as polyvinyl alcohol, povidone, hydroxypropylmethylcellulose, poloxamers, carboxymethylcellulose, carbomers and hydroxyethylcellulose.
- the preferred preservatives which may be used in the solutions according to the invention include benzalkonium chloride, chlorobutanol, thimerosal, phenyl mercury acetate and phenyl mercury nitrate.
- the penetration promoters may be, for example, surfactants, specific organic solvents such as dimethylsulfoxide and other sulfoxides, dimethylacetamide and pyrrolidone, specific amides of heterocyclic amines, glycols such as propyleneglycol, propylene carbonate, oleic acid, alkylamines and derivatives thereof, various cationic, anionic, non-ionogenic and amphoteric surfactants and the like.
- specific organic solvents such as dimethylsulfoxide and other sulfoxides, dimethylacetamide and pyrrolidone
- specific amides of heterocyclic amines such as propyleneglycol, propylene carbonate, oleic acid, alkylamines and derivatives thereof
- various cationic, anionic, non-ionogenic and amphoteric surfactants and the like.
- Substances may be added as necessary or as desired in order to adjust the tonicity of the solution.
- Such substances include salts and especially sodium chloride, potassium chloride, mannitol and glycerol or other suitable physiologically acceptable agents for adjusting tonicity, without restricting the invention to the above.
- buffers and substances may be used to adjust the pH, provided that the preparation obtained is physiologically acceptable.
- These buffers might include acetate buffer, citrate buffer, phosphate buffer and borate buffer.
- physiologically acceptable antioxidants which may be used according to the invention include sodium metabisulphite, sodium thiosulphate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene, without restricting the invention to this list.
- carrier components which may be incorporated in the solutions according to the invention are chelating agents.
- the preferred chelating agent is disodium edetate (Na-EDTA), although other chelating agents may also be used instead of or in conjunction with disodium edetate.
- topically administered aqueous solutions according to the invention may be applied either to the conjunctiva or to the nasal mucous membrane. Solutions for ophthalmic use are of equal importance to solutions for nasal application for the purposes of the present invention.
- the invention relates not only to the solutions according to the invention mentioned hereinbefore but also to the use of the above-mentioned topically administered aqueous solutions for inhibiting the influx of neutrophils and eosinophils into the tissue of the ocular conjunctiva or the tissue of the nasal mucous membrane.
- the present invention also relates to the use of epinastin, optionally in the form of its racemate, its enantiomers and optionally in the form of the pharmacologically acceptable acid addition salts thereof, for producing the topically administered aqueous solutions according to the invention for treating disorders of the ocular conjunctiva or the nasal mucous membranes in which there is therapeutic value in inhibiting the influx of neutrophils and cosinophils into the tissue of the ocular conjunctiva or the nasal mucous membrane in allergic reactions.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- General Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Detergent Compositions (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/271,180 US20030050303A1 (en) | 1999-11-12 | 2002-10-15 | Solutions containing epinastin |
US11/215,165 US20050288274A1 (en) | 1999-11-12 | 2005-08-30 | Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane |
US11/734,512 US20070185082A1 (en) | 1999-11-12 | 2007-04-12 | Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane |
US11/734,507 US20070197503A1 (en) | 1999-11-12 | 2007-04-12 | Solutions containing epinastin |
US11/863,008 US7429602B2 (en) | 1999-11-12 | 2007-09-27 | Treating conjunctivitis by topically administering an epinastine solution to the conjunctiva |
US12/394,684 US20090239842A1 (en) | 1999-11-12 | 2009-02-27 | Solutions containing epinastin |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19954516A DE19954516A1 (de) | 1999-11-12 | 1999-11-12 | Epinastin-haltige Lösungen |
DE19954516.2 | 1999-11-12 | ||
US16777199P | 1999-11-29 | 1999-11-29 | |
US70665000A | 2000-11-06 | 2000-11-06 | |
US10/271,180 US20030050303A1 (en) | 1999-11-12 | 2002-10-15 | Solutions containing epinastin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US70665000A Continuation | 1999-11-12 | 2000-11-06 |
Related Child Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/215,165 Continuation US20050288274A1 (en) | 1999-11-12 | 2005-08-30 | Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane |
US11/734,507 Continuation US20070197503A1 (en) | 1999-11-12 | 2007-04-12 | Solutions containing epinastin |
US11/734,512 Continuation US20070185082A1 (en) | 1999-11-12 | 2007-04-12 | Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane |
US11/863,008 Continuation US7429602B2 (en) | 1999-11-12 | 2007-09-27 | Treating conjunctivitis by topically administering an epinastine solution to the conjunctiva |
US12/394,684 Continuation US20090239842A1 (en) | 1999-11-12 | 2009-02-27 | Solutions containing epinastin |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030050303A1 true US20030050303A1 (en) | 2003-03-13 |
Family
ID=7928843
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/271,180 Abandoned US20030050303A1 (en) | 1999-11-12 | 2002-10-15 | Solutions containing epinastin |
US11/215,165 Abandoned US20050288274A1 (en) | 1999-11-12 | 2005-08-30 | Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane |
US11/734,512 Abandoned US20070185082A1 (en) | 1999-11-12 | 2007-04-12 | Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane |
US11/734,507 Abandoned US20070197503A1 (en) | 1999-11-12 | 2007-04-12 | Solutions containing epinastin |
US11/863,008 Expired - Lifetime US7429602B2 (en) | 1999-11-12 | 2007-09-27 | Treating conjunctivitis by topically administering an epinastine solution to the conjunctiva |
US12/394,684 Abandoned US20090239842A1 (en) | 1999-11-12 | 2009-02-27 | Solutions containing epinastin |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/215,165 Abandoned US20050288274A1 (en) | 1999-11-12 | 2005-08-30 | Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane |
US11/734,512 Abandoned US20070185082A1 (en) | 1999-11-12 | 2007-04-12 | Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane |
US11/734,507 Abandoned US20070197503A1 (en) | 1999-11-12 | 2007-04-12 | Solutions containing epinastin |
US11/863,008 Expired - Lifetime US7429602B2 (en) | 1999-11-12 | 2007-09-27 | Treating conjunctivitis by topically administering an epinastine solution to the conjunctiva |
US12/394,684 Abandoned US20090239842A1 (en) | 1999-11-12 | 2009-02-27 | Solutions containing epinastin |
Country Status (40)
Country | Link |
---|---|
US (6) | US20030050303A1 (ja) |
EP (1) | EP1231920B1 (ja) |
JP (1) | JP2003514021A (ja) |
KR (1) | KR100758842B1 (ja) |
CN (1) | CN1292752C (ja) |
AR (1) | AR026424A1 (ja) |
AT (1) | ATE353218T1 (ja) |
AU (2) | AU784017B2 (ja) |
BG (1) | BG65775B1 (ja) |
BR (1) | BR0015477A (ja) |
CA (1) | CA2391076C (ja) |
CO (1) | CO5251448A1 (ja) |
CY (1) | CY1106375T1 (ja) |
CZ (1) | CZ302483B6 (ja) |
DE (2) | DE19954516A1 (ja) |
DK (1) | DK1231920T3 (ja) |
EA (1) | EA006937B1 (ja) |
EE (1) | EE05395B1 (ja) |
ES (1) | ES2281359T3 (ja) |
HK (1) | HK1052303B (ja) |
HR (1) | HRP20020404B1 (ja) |
HU (1) | HU229502B1 (ja) |
IL (2) | IL149501A0 (ja) |
ME (1) | MEP36708A (ja) |
MX (1) | MXPA02004556A (ja) |
MY (1) | MY130441A (ja) |
NO (1) | NO329417B1 (ja) |
NZ (1) | NZ519425A (ja) |
PE (1) | PE20010826A1 (ja) |
PL (1) | PL198879B1 (ja) |
PT (1) | PT1231920E (ja) |
RS (1) | RS50173B (ja) |
SA (1) | SA01210658B1 (ja) |
SI (1) | SI1231920T1 (ja) |
SK (1) | SK287343B6 (ja) |
TR (1) | TR200201270T2 (ja) |
TW (1) | TWI225401B (ja) |
UA (1) | UA74563C2 (ja) |
WO (1) | WO2001035962A1 (ja) |
ZA (1) | ZA200203683B (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040247686A1 (en) * | 2003-04-04 | 2004-12-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions comprising epinastine for the treatment of skin diseases |
US20050084527A1 (en) * | 2002-08-02 | 2005-04-21 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations containing combinations of epinastine, pseudoephedrine, and methylephedrine |
US20060073172A1 (en) * | 2004-10-01 | 2006-04-06 | Schneider L W | Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure |
US20070197503A1 (en) * | 1999-11-12 | 2007-08-23 | Volker Trach | Solutions containing epinastin |
US7378082B1 (en) | 2007-11-05 | 2008-05-27 | Inspire Pharmaceuticals, Inc. | Method for treating allergic rhinitis without adverse effects |
US20080194544A1 (en) * | 2007-02-08 | 2008-08-14 | Ramesh Krishnamoorthy | Aqueous formulations of epinastine for treating allergic rhinitis |
US20090143359A1 (en) * | 2005-07-08 | 2009-06-04 | Akiharu Isowaki | Percutaneously Absorptive Ophthalmic Preparation Comprising Epinastine |
CN112969465A (zh) * | 2018-10-31 | 2021-06-15 | 参天制药株式会社 | 抑制软性隐形眼镜变质的眼科用组合物 |
CN115397430A (zh) * | 2020-04-16 | 2022-11-25 | 参天制药株式会社 | 含有依匹斯汀或其盐的水性组合物 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1468696A1 (en) * | 2003-04-17 | 2004-10-20 | Boehringer Ingelheim International GmbH | Combinations of epinastine and antiphlogisitcs as new pharmaceutical compositions for the treatment of skin diseases |
WO2008098122A2 (en) * | 2007-02-08 | 2008-08-14 | Inspire Pharmaceuticals, Inc. | Method for treating allergic rhinitis without adverse effects |
EP2464387A4 (en) * | 2009-08-12 | 2013-05-15 | Seros Medical Llc | DEUTERATED WATER SOLUTION AND RIBOFLAVIN FOR EXTENDED OXYGEN SINGULET LIFETIME IN THE TREATMENT OF OCULAR TISSUE AND METHOD OF USE |
TWI544922B (zh) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠(olopatadine)眼用組成物 |
EP2630952A1 (en) * | 2012-02-23 | 2013-08-28 | Novagali Pharma S.A. | Self-preserved oil dispersions comprising boric acid |
DK2934510T3 (da) * | 2012-12-19 | 2021-01-25 | Novartis Ag | Lfa-1-inhibitorformuleringer |
CN104491876A (zh) * | 2014-12-23 | 2015-04-08 | 中国药科大学 | 含玻璃酸钠的依匹斯汀滴眼液及其制备方法 |
ITUB20153950A1 (it) * | 2015-09-28 | 2017-03-28 | Tred Srl | Dispositivo nasale in grado di attivare il riflesso rino-palatale per l'igienizzazione rinofaringea |
JP6134853B1 (ja) * | 2016-10-28 | 2017-05-24 | 参天製薬株式会社 | エピナスチン含有点眼液 |
JP6635974B2 (ja) * | 2017-04-24 | 2020-01-29 | 参天製薬株式会社 | エピナスチン含有点眼液 |
KR102582048B1 (ko) * | 2017-05-01 | 2023-09-21 | 산텐 세이야꾸 가부시키가이샤 | 점안제 |
JP6736752B2 (ja) * | 2019-12-17 | 2020-08-05 | 参天製薬株式会社 | エピナスチン含有点眼液 |
JP7118579B1 (ja) | 2020-04-16 | 2022-08-16 | 参天製薬株式会社 | エピナスチン又はその塩を含有する水性組成物 |
JP2020169213A (ja) * | 2020-07-15 | 2020-10-15 | 参天製薬株式会社 | エピナスチン含有点眼液 |
CN115448927A (zh) * | 2022-10-20 | 2022-12-09 | 重庆瑞泊莱医药科技有限公司 | 一种氢溴酸依匹斯汀晶型ii及其制备方法 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8632A (en) * | 1852-01-06 | George hess | ||
US104017A (en) * | 1870-06-07 | Improvement in embroidering attachment for sewing-machines | ||
US151541A (en) * | 1874-06-02 | Improvement in hay-loaders | ||
US181478A (en) * | 1876-08-22 | Improvement in water-wheels | ||
US203021A (en) * | 1878-04-30 | Improvement in side-bar wagons | ||
US215396A (en) * | 1879-05-13 | Improvement in loom-temples | ||
US228359A (en) * | 1880-06-01 | jones | ||
US5668133A (en) * | 1992-12-09 | 1997-09-16 | Alcon Laboratories, Inc. | Ophthalmic compositions comprising emedastine and methods for their use |
US20020037297A1 (en) * | 1997-09-22 | 2002-03-28 | Crespo Maria Del Carmen Diez | Process for the topical treatment of rhinitis, conjunctivitis cold, and cold-like and flu symptoms |
US6403790B1 (en) * | 1999-12-03 | 2002-06-11 | Boehringer Ingelheim Pharma Kg | Process for the production of epinastine hydrochloride in the high-melting crystal modification |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3008944A1 (de) * | 1980-03-08 | 1981-09-24 | C.H. Boehringer Sohn, 6507 Ingelheim | Dibenzimidazoazepine, ihre herstellung und verwendung |
DE4102148A1 (de) * | 1991-01-25 | 1992-07-30 | Boehringer Ingelheim Kg | Verfahren zur herstellung von 3-amino-9,13b-dihydro-1h-dibenz-(c,f)imidazol(1,5-a)azepin-hydrochlorid |
EE03509B2 (et) * | 1995-06-27 | 2015-02-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Stabiilsed ravimikompositsioonid kandegaasita aerosoolide saamiseks |
DE19542281C2 (de) * | 1995-11-14 | 1997-12-04 | Boehringer Ingelheim Kg | Verwendung von Epinastin für die Behandlung der Migräne |
AU3869197A (en) * | 1996-08-30 | 1998-03-19 | Kyoto Pharmaceutical Industries, Ltd. | Remedies for allergic dermatitis |
DE19653969A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
US20030215396A1 (en) * | 1999-09-15 | 2003-11-20 | Boehringer Ingelheim Pharma Kg | Method for the production of propellant gas-free aerosols from aqueous medicament preparations |
DE19954516A1 (de) * | 1999-11-12 | 2001-05-17 | Boehringer Ingelheim Int | Epinastin-haltige Lösungen |
CN1376066A (zh) * | 1999-11-18 | 2002-10-23 | 爱尔康公司 | H1拮抗剂和安全类固醇的治疗眼病的用途 |
FR2803520B1 (fr) * | 2000-01-12 | 2002-09-20 | Ceva Sante Animale | Procede pour augmenter la production d'oeufs et consolider la coquille des oeufs chez les volailles |
US20020094345A1 (en) * | 2000-10-06 | 2002-07-18 | Sara Abelaira | Pharmaceutical compositions containing epinastine and pseudoephedrine |
US20020151541A1 (en) * | 2000-10-31 | 2002-10-17 | Michel Pairet | Pharmaceutical compositions containing tiotropium salts and antihistamines and their use |
US20020137764A1 (en) * | 2000-10-31 | 2002-09-26 | Karin Drechsel | Inhalable formulation of a solution containing a tiotropium salt |
DE10119718A1 (de) * | 2001-04-21 | 2002-10-31 | Boehringer Ingelheim Pharma | Verfahren zur kontinuierlichen Herstellung inhalierfähiger Arzneistoffe, Vorrichtung zur Durchführung des Verfahrens und nach diesem Verfahren hergestellter Arzneistoff |
WO2002098112A2 (en) * | 2001-05-29 | 2002-12-05 | Transchip, Inc. | Patent application cmos imager for cellular applications and methods of using such |
US20030104017A1 (en) * | 2001-10-26 | 2003-06-05 | Boehringer Ingelheim International Gmbh | Epinastine formulation for oral administration |
EP1350512A1 (en) * | 2002-04-03 | 2003-10-08 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations |
US6863848B2 (en) * | 2002-08-30 | 2005-03-08 | Signet Armorlite, Inc. | Methods for preparing composite photochromic ophthalmic lenses |
JP2007145316A (ja) * | 2005-10-27 | 2007-06-14 | Nissan Motor Co Ltd | 遮光装置とサンバイザーとサンルーフユニット |
-
1999
- 1999-11-12 DE DE19954516A patent/DE19954516A1/de not_active Withdrawn
-
2000
- 2000-10-14 MX MXPA02004556A patent/MXPA02004556A/es active IP Right Grant
- 2000-10-14 SI SI200030938T patent/SI1231920T1/sl unknown
- 2000-10-14 JP JP2001537955A patent/JP2003514021A/ja active Pending
- 2000-10-14 UA UA2002064760A patent/UA74563C2/uk unknown
- 2000-10-14 BR BR0015477-6A patent/BR0015477A/pt not_active Application Discontinuation
- 2000-10-14 IL IL14950100A patent/IL149501A0/xx unknown
- 2000-10-14 EE EEP200200246A patent/EE05395B1/xx unknown
- 2000-10-14 AU AU11381/01A patent/AU784017B2/en not_active Expired
- 2000-10-14 PL PL364028A patent/PL198879B1/pl unknown
- 2000-10-14 PT PT00972763T patent/PT1231920E/pt unknown
- 2000-10-14 EP EP00972763A patent/EP1231920B1/de not_active Expired - Lifetime
- 2000-10-14 AT AT00972763T patent/ATE353218T1/de active
- 2000-10-14 ES ES00972763T patent/ES2281359T3/es not_active Expired - Lifetime
- 2000-10-14 WO PCT/EP2000/010122 patent/WO2001035962A1/de active IP Right Grant
- 2000-10-14 CN CNB00815547XA patent/CN1292752C/zh not_active Expired - Lifetime
- 2000-10-14 RS YUP-336/02A patent/RS50173B/sr unknown
- 2000-10-14 EA EA200200492A patent/EA006937B1/ru not_active IP Right Cessation
- 2000-10-14 ME MEP-367/08A patent/MEP36708A/xx unknown
- 2000-10-14 CA CA002391076A patent/CA2391076C/en not_active Expired - Lifetime
- 2000-10-14 NZ NZ519425A patent/NZ519425A/en not_active IP Right Cessation
- 2000-10-14 DK DK00972763T patent/DK1231920T3/da active
- 2000-10-14 DE DE50014041T patent/DE50014041D1/de not_active Expired - Lifetime
- 2000-10-14 HU HU0203773A patent/HU229502B1/hu unknown
- 2000-10-14 SK SK830-2002A patent/SK287343B6/sk not_active IP Right Cessation
- 2000-10-14 KR KR1020027006058A patent/KR100758842B1/ko active IP Right Grant
- 2000-10-14 CZ CZ20021956A patent/CZ302483B6/cs not_active IP Right Cessation
- 2000-10-14 TR TR2002/01270T patent/TR200201270T2/xx unknown
- 2000-11-10 TW TW089123815A patent/TWI225401B/zh not_active IP Right Cessation
- 2000-11-10 AR ARP000105932A patent/AR026424A1/es not_active Suspension/Interruption
- 2000-11-10 MY MYPI20005284A patent/MY130441A/en unknown
- 2000-11-10 PE PE2000001201A patent/PE20010826A1/es not_active Application Discontinuation
- 2000-11-10 CO CO00085787A patent/CO5251448A1/es not_active Application Discontinuation
-
2001
- 2001-01-20 SA SA01210658A patent/SA01210658B1/ar unknown
-
2002
- 2002-05-07 IL IL149501A patent/IL149501A/en active IP Right Grant
- 2002-05-08 NO NO20022201A patent/NO329417B1/no not_active IP Right Cessation
- 2002-05-09 HR HR20020404A patent/HRP20020404B1/xx not_active IP Right Cessation
- 2002-05-09 ZA ZA200203683A patent/ZA200203683B/xx unknown
- 2002-05-09 BG BG106681A patent/BG65775B1/bg unknown
- 2002-10-15 US US10/271,180 patent/US20030050303A1/en not_active Abandoned
-
2003
- 2003-06-30 HK HK03104651.9A patent/HK1052303B/zh not_active IP Right Cessation
-
2005
- 2005-08-30 US US11/215,165 patent/US20050288274A1/en not_active Abandoned
-
2006
- 2006-04-12 AU AU2006201541A patent/AU2006201541A1/en not_active Abandoned
-
2007
- 2007-03-13 CY CY20071100351T patent/CY1106375T1/el unknown
- 2007-04-12 US US11/734,512 patent/US20070185082A1/en not_active Abandoned
- 2007-04-12 US US11/734,507 patent/US20070197503A1/en not_active Abandoned
- 2007-09-27 US US11/863,008 patent/US7429602B2/en not_active Expired - Lifetime
-
2009
- 2009-02-27 US US12/394,684 patent/US20090239842A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8632A (en) * | 1852-01-06 | George hess | ||
US104017A (en) * | 1870-06-07 | Improvement in embroidering attachment for sewing-machines | ||
US151541A (en) * | 1874-06-02 | Improvement in hay-loaders | ||
US181478A (en) * | 1876-08-22 | Improvement in water-wheels | ||
US203021A (en) * | 1878-04-30 | Improvement in side-bar wagons | ||
US215396A (en) * | 1879-05-13 | Improvement in loom-temples | ||
US228359A (en) * | 1880-06-01 | jones | ||
US5668133A (en) * | 1992-12-09 | 1997-09-16 | Alcon Laboratories, Inc. | Ophthalmic compositions comprising emedastine and methods for their use |
US20020037297A1 (en) * | 1997-09-22 | 2002-03-28 | Crespo Maria Del Carmen Diez | Process for the topical treatment of rhinitis, conjunctivitis cold, and cold-like and flu symptoms |
US6403790B1 (en) * | 1999-12-03 | 2002-06-11 | Boehringer Ingelheim Pharma Kg | Process for the production of epinastine hydrochloride in the high-melting crystal modification |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070197503A1 (en) * | 1999-11-12 | 2007-08-23 | Volker Trach | Solutions containing epinastin |
US20080009476A1 (en) * | 1999-11-12 | 2008-01-10 | Volker Trach | Treating conjunctivitis by topically administering an epinastine solution to the conjunctiva |
US7429602B2 (en) | 1999-11-12 | 2008-09-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Treating conjunctivitis by topically administering an epinastine solution to the conjunctiva |
US20090239842A1 (en) * | 1999-11-12 | 2009-09-24 | Volker Trach | Solutions containing epinastin |
US20050084527A1 (en) * | 2002-08-02 | 2005-04-21 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations containing combinations of epinastine, pseudoephedrine, and methylephedrine |
US20040247686A1 (en) * | 2003-04-04 | 2004-12-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions comprising epinastine for the treatment of skin diseases |
US20060073172A1 (en) * | 2004-10-01 | 2006-04-06 | Schneider L W | Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure |
US20090143359A1 (en) * | 2005-07-08 | 2009-06-04 | Akiharu Isowaki | Percutaneously Absorptive Ophthalmic Preparation Comprising Epinastine |
US20080194544A1 (en) * | 2007-02-08 | 2008-08-14 | Ramesh Krishnamoorthy | Aqueous formulations of epinastine for treating allergic rhinitis |
US7378082B1 (en) | 2007-11-05 | 2008-05-27 | Inspire Pharmaceuticals, Inc. | Method for treating allergic rhinitis without adverse effects |
CN112969465A (zh) * | 2018-10-31 | 2021-06-15 | 参天制药株式会社 | 抑制软性隐形眼镜变质的眼科用组合物 |
CN115397430A (zh) * | 2020-04-16 | 2022-11-25 | 参天制药株式会社 | 含有依匹斯汀或其盐的水性组合物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7429602B2 (en) | Treating conjunctivitis by topically administering an epinastine solution to the conjunctiva | |
CA2543452C (en) | Therapeutic agent for keratoconjunctival disorder | |
US7875271B2 (en) | Ophthalmic composition comprising xanthan gum and glucose | |
US5021410A (en) | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure | |
KR100776577B1 (ko) | 점안제 | |
US20050009902A1 (en) | Remedies for pruritus | |
EP0630240B1 (en) | Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (gaba) agonists | |
EP4248970A1 (en) | Opthalmic compositions comprising cetirizine and tocofersolan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, FKA. BOEHRINGER INGELHEIM PHARMA GMBH;REEL/FRAME:019796/0095 Effective date: 20070606 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |